Did an Israeli firm find a cure for cancer? Scientists aren't so sure..

Cancer Research UK declined to comment on the company’s claim in the absence of a peer-reviewed paper.

A team of scientists at a biotech company in Israel has claimed preliminary research on mice suggests they will have a cure for all forms of cancer within a year.

Sadly, their claims were shot down by fellow scientists.

Dan Aridor, chairman of the board of Accelerated Evolution Biotechnologies Ltd.,, and CEO Dr. Ilan Morad told the Jerusalem Post results of pre-clinical trials have been very good.

But fellow scientists quickly rejected the claims, calling them “spurious,” “highly irresponsible,” “unsubstantiated” and even “cruel.”

The sceptical scientists note that the research group has not published any findings to back up their claims, as is traditional in the science community.

Cancer Research UK declined to comment on the company’s claim in the absence of a peer-reviewed paper.

Similarly, the Food and Drug Administration in the US refused to comment on the company’s treatment when approached by the TV network CNBC.

Morad told The Times of Israel earlier this week that it has not published its research in medical journals because it “can’t afford” to do so.

But reputable scientific journals, that are peer reviewed and highly respected, do not charge to publish serious scientific research, though the process can be rigorous.

Writing in Forbes, Victoria Forster, a cancer researcher and child cancer survivor, called AEBI less than forthcoming with information about their alleged cure.

“Delving into what the company does supply, there are two graphs and some pictures taken down a microscope, much less than I provided from a 6-week undergraduate research project a decade ago,” she wrote.

She also calls a claim that one cure will work for all of the over 200 different types of cancer out there a “huge red flag” that such a claim is “highly unlikely.”

The CEO of the Israel Advanced Technology Industries group said the whole situation has “damaged the image of Israel’s life sciences industry.”